Salthouse Daniel, Goulding Peter D, Reay Sophie L, Jackson Emma L, Xu Chenlong, Ahmed Rochelle, Mearns-Spragg Andrew, Novakovic Katarina, Hilkens Catharien M U, Ferreira Ana Marina
School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Front Bioeng Biotechnol. 2024 Jul 26;12:1391728. doi: 10.3389/fbioe.2024.1391728. eCollection 2024.
Collagen is extensively utilised in regenerative medicine due to its highly desirable properties. However, collagen is typically derived from mammalian sources, which poses several limitations, including high cost, potential risk of immunogenicity and transmission of infectious diseases, and ethical and religious constraints. Jellyfish-sourced type 0 collagen represents a safer and more environmentally sustainable alternative collagen source.
Thus, we investigated the potential of jellyfish collagen-based hydrogels, obtained from Rhizostoma pulmo (R. pulmo) jellyfish, to be utilised in regenerative medicine. A variety of R. pulmo collagen hydrogels (RpCol hydrogels) were formed by adding a range of chemical crosslinking agents and their physicochemical and biological properties were characterised to assess their suitability for regenerative medicine applications.
The characteristic chemical composition of RpCol was confirmed by Fourier-transform infrared spectroscopy (FTIR), and the degradation kinetics, morphological, and rheological properties of RpCol hydrogels were shown to be adaptable through the addition of specific chemical crosslinking agents. The endotoxin levels of RpCol were below the Food and Drug Administration (FDA) limit for medical devices, thus allowing the potential use of RpCol . 8-arm polyethylene glycol succinimidyl carboxyl methyl ester (PEG-SCM)-crosslinked RpCol hydrogels preserved the viability and induced a significant increase in the metabolic activity of immortalised human mesenchymal stem/stromal cells (TERT-hMSCs), therefore demonstrating their potential to be utilised in a wide range of regenerative medicine applications.
胶原蛋白因其极具吸引力的特性而在再生医学中得到广泛应用。然而,胶原蛋白通常来源于哺乳动物,这带来了一些限制,包括成本高、存在免疫原性和传染病传播的潜在风险,以及伦理和宗教限制。源自水母的0型胶原蛋白是一种更安全、更具环境可持续性的替代胶原蛋白来源。
因此,我们研究了从黄斑海蜇(R. pulmo)水母中提取的基于水母胶原蛋白的水凝胶在再生医学中的应用潜力。通过添加一系列化学交联剂形成了多种黄斑海蜇胶原蛋白水凝胶(RpCol水凝胶),并对其物理化学和生物学特性进行了表征,以评估它们在再生医学应用中的适用性。
通过傅里叶变换红外光谱(FTIR)证实了RpCol的特征化学成分,并且通过添加特定的化学交联剂,RpCol水凝胶的降解动力学、形态学和流变学特性显示出可适应性。RpCol的内毒素水平低于美国食品药品监督管理局(FDA)对医疗器械的限制,因此使得RpCol有潜在的使用价值。8-臂聚乙二醇琥珀酰亚胺基羧基甲酯(PEG-SCM)交联的RpCol水凝胶保留了永生化人间充质干/基质细胞(TERT-hMSCs)的活力,并显著提高了其代谢活性,因此证明了它们在广泛的再生医学应用中的潜力。